eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
3/2023
vol. 25
 
Share:
Send email
Share:
Review paper

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice

Dagmara Mirowska-Guzel
1
,
Magdalena Niedzielko
1
,
Rafał Kułakowski
2

  1. Chair and Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
  2. Medical student, Medical University of Warsaw, Warsaw, Poland
Family Medicine & Primary Care Review 2023; 25(3): 353–359
DOI: https://doi.org/10.5114/fmpcr.2023.130097
Online publish date: 2023/09/30
Article file
- 18 FM&PCR 3 23 - R - Mirowska-Guzel - 1365 - Managing.pdf  [0.45 MB]
Get citation
 
PlumX metrics:
 
1. Paxlovid 150 mg + 100 mg film-coated tablets Summary of Product Characteristics [cited 21.04.2023]. Available from URL: https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf.
2. European Medicines Agency Paxlovid Authorisation details [cited 09.05.2023.] Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/paxlovid.
3. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022; 386(15): 1397–1408.
4. Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis 2023; 23(7): 806–815.
5. Marzi M, Vakil MK, Bahmanyar M, et al. Paxlovid: Mechanism of Action, Synthesis, and In Silico Study. Biomed Res Int 2022; 2022: 7341493, doi: 10.1155/2022/7341493.
6. Stockley’s Drug Interactions: Medicines Complete online platform [cited 09.05.2023]. Available from URL: https://about.medicinescomplete.com/publication/stockleys-drug-interactions/.
7. Lexicomp Drug Interactions [cited 09.05.2023]. Available from URL: https://www.wolterskluwer.com/en/solutions/lexicomp/resources/lexicomp-user-academy/drug-interactions-analysis.
8. Medscape Drug Interaction Checker [cited 09.05.2023]. Available from URL: https://reference.medscape.com/drug-interactionchecker.
9. Kongsholm GG, Nielsen AKT, Damkier P. Drug interaction databases in medical literature: transparency of ownership, funding, classification algorithms, level of documentation, and staff qualifications. A systematic review. Eur J Clin Pharmacol 2015; 71(11): 1397–1402.
10. Shini Rubina SK, Pharm D, Anuba PA, et al. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: a evidence-based review from six databases. Diabetes Metab Syndr 2022; 16(3): 102451.
11. Tornio A, Filppula AM, Niemi M, et al. Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation. Clin Pharmacol Ther 2019; 105(6): 1345–1361.
12. Roberts AG, Gibbs ME. Mechanisms and the clinical relevance of complex drug-drug interactions. Clin Pharmacol 2018; 10: 123–34.
13. Zhao M, Ma J, Li M, et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int J Mol Sci 2021; 22(23): 12808, doi: 10.3390/ijms222312808.
14. U.S. Food and drug administration. Drug Development and Drug Interactions. Table of Substrates, Inhibitors and Inducers [cited 22.04.2023]. Available from URL: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers.
15. Flockhart DA, Thacker D, McDonald C, et al. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Division of Clinical Pharmacology, Indiana University School of Medicine (Updated 2021) [cited 22.04.2023]. Available from URL: https://drug-interactions.medicine.iu.edu.
16. Gerhard Nahler. Dictionary of Pharmaceutical Medicine. Cham: Springer International Publishing AG, 2017 [cited 15.05.2023]. Available from: ProQuest Ebook Central.
17. Boffito M, Back D, Gatell JM. Twenty years of boosting antiretroviral agents: where are we today? AIDS 2015; 29(17): 2229–2233.
18. National Institutes of Health Coronavirus Disease 2019 (COVID-19) Treatment guidelines. Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications [cited 03.05.2023]. Available from URL: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/.
19. Marzolini C, Kuritzkes DR, Marra F, et al. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clin Pharmacol Ther 2022; 112(6): 1191–1200.
20. Lemaitre F, Grégoire M, Monchaud C, et al. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT). Therapie 2022; 77(5): 509–521.
21. University of Liverpool COVID-19 Drug interaction database [cited 29.04.2023]. Available from URL: https://www.covid19-druginteractions.org/.
22. EU Risk management plan for Paxlovid (PF-07321332/Ritonavir): Date of final sign off: 01 September 2022 [cited 21.04.2023]. Available from URL: https://www.ema.europa.eu/en/documents/rmp-summary/paxlovid-epar-risk-management-plan_en.pdf.
23. Stader F, Kinvig H, Battegay M, et al. Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. Antimicrob Agents Chemother 2018; 62(7): e00717-18, doi: 10.1128/AAC.00717-18.
24. Abraham S, Nohria A, Neilan TG, et al. Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir in Patients with COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol 2022; 80(20): 1912–1924.
25. Katzenmaier S, Markert C, Riedel K-D, et al. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther 2011; 90(5): 666–673.
26. Loos NHC, Beijnen JH, Schinkel AH. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomed Pharmacother 2023; 162: 114636.
27. Stader F, Khoo S, Stoeckle M, et al. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug inter-acting effect. J Antimicrob Chemother 2020; 75(10): 3084–3086.
28. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 2005; 78(6): 664–674.
29. Cattaneo D, Cossu MV, Rizzardini G. Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV. Expert Opin Drug Metab Toxicol 2019; 15(11): 927–935.
30. Sinthrome 1 mg Tablets Summary of Product Characteristics [cited 06.05.2023]. Available from URL: https://www.medicines.org.uk/emc/product/2058/smpc#gref.
31. Wanounou M, Caraco Y, Levy RH, et al. Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy. Clin Pharmacokinet 2022; 61(9): 1219–1236.
32. Sluijters A, Lemaitre F, Belkhir L, et al. A Case Report of Safe Coadministration of Amiodarone with Short-Term Treatment Nirmatrelvir-Ritonavir. Clin Pharmacol Ther 2023; 113(4): 768–769.
33. Lange NW, Salerno DM, Jennings DL, et al. Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug inter-actions with transplant immunosuppressants. Am J Transplant 2022; 22(7): 1925–1926.
34. Tang Y, Li Y, Song T. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies. Front Immunol 2023; 14: 1150341.
35. Vazquez SR, Wilson AS, Witt DM. Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series. J Thromb Thrombolysis 2022; 54(4): 583–586.
36. European Medicines Agency (EMA) List of medicinal products under additional monitoring. [cited 06.05.2023]. Available from URL: https://www.ema.europa.eu/en/documents/additional-monitoring/list-medicinal-products-under-additional-monitoring_en.pdf.
Copyright: © 2023 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.